- ￥2300 - 5900
- 齐源
- 127651
- 国产/进口
- 2025年07月08日
- FC
- 大鼠
- 小鼠
6 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 供应商：
齐源
- 库存：
999
- 靶点：
Ly-6G
- 级别：
Ly-6G Antibody
- 目录编号：
Ly-6G Antibody
- 克隆性：
单克隆
- 抗原来源：
大鼠
- 保质期：
Ly-6G Antibody
- 抗体英文名：
Fire™ 750 anti-mouse Ly-6G Antibody-APC
- 抗体名：
Ly-6G Antibody
- 标记物：
APC
- 宿主：
大鼠
- 适应物种：
小鼠
- 免疫原：
Ly-6G Antibody
- 亚型：
Ly-6G Antibody
- 形态：
Ly-6G Antibody
- 应用范围：
FC
- 保存条件：
2-8℃
- 浓度：
0.2 mg/ml
- 规格：
25 µg/100 µg
| 规格： | 25 µg | 产品价格： | ￥2300.0 |
|---|---|---|---|
| 规格： | 100 µg | 产品价格： | ￥5900.0 |
Fire™ 750 anti-mouse Ly-6G Antibody-APC详细如下：
Description ：Lymphocyte antigen 6 complex, locus G (Ly-6G), a 21-25 kD GPI-anchored protein, isexpressed on the majority of myeloid cells in bone marrow and peripheral granulocytes.
Verified Reactivity ：Mouse
Antibody Type ：Monoclonal
Host Species ：Rat
Immunogen ：Ly-6G transfected EL-4J cell line.
Formulation ：Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation ：The antibody was purified by affinity chromatography and conjugated with APC/Fire™ 750 underoptimal conditions.
Concentration ：0.2 mg/ml
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C, and protected fromprolonged exposure to light. Do not freeze.
Application ：FC - Quality tested
Recommended Usage ：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cellsin 100 µl volume. It is recommended that the reagent be titrated for optimal performance for eachapplication.
* APC/Fire™ 750 has a maximum excitation of 650 nm and a maximum emission of 774 nm.
Description ：Lymphocyte antigen 6 complex, locus G (Ly-6G), a 21-25 kD GPI-anchored protein, isexpressed on the majority of myeloid cells in bone marrow and peripheral granulocytes.
Verified Reactivity ：Mouse
Antibody Type ：Monoclonal
Host Species ：Rat
Immunogen ：Ly-6G transfected EL-4J cell line.
Formulation ：Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation ：The antibody was purified by affinity chromatography and conjugated with APC/Fire™ 750 underoptimal conditions.
Concentration ：0.2 mg/ml
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C, and protected fromprolonged exposure to light. Do not freeze.
Application ：FC - Quality tested
Recommended Usage ：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cellsin 100 µl volume. It is recommended that the reagent be titrated for optimal performance for eachapplication.
* APC/Fire™ 750 has a maximum excitation of 650 nm and a maximum emission of 774 nm.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
Application References(PubMed link indicatesBioLegend citation)：
1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (FC)
2. Daley JM, et al. 2008. J. Leukocyte Biol. 83:1. (FC)
3. Dietlin TA, et al. 2007. J. Leukocyte Biol. 81:1205. (FC)
4. Daley J, et al. 2007. J. Leukocyte Biol. doi:10.1189. (Deplete) PubMed
5. Tadagavadi RK, et al. 2010. J. Immunol. 185:4904. PubMed
6. Sumagin R, et al. 2010. J. Immunol. 185:7057. PubMed
7. Guiducci C, et al. 2010. J. Exp Med. 207:2931. PubMed
8. Fujita M, et al. 2011. Cancer Res. 71:2664. PubMed
9. Van Leeuwen, et al. 2008. Arterioscler. Thromb. Vasc. Biol. 28:84. (IHC)
10. Kowanetz M, et al. 2010. P. Natl. Acad. Sci. USA 107:21248. [supplementary data] (IHC)
11. Esbona K, et al. 2016. Breast Cancer Res. 18:35. (IHC)
12. Wojtasiak M, et al. 2010. J. Gen. Virol. 91:2158. (FC, Deplete)
13. Jaeger BN, et al. 2012. J. Exp. Med. 209:565. (Deplete)
14. Wozniak KL, et al. 2012. BMC Immunol. 13:65 (FC, Deplete)
15. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
16. Ng LG, et al. 2011. J Invest. Dermatol. 131:2058. PubMed
17. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
18. McCartney-Francis, N, et al. 2014. J Leukoc. Biol. 96:917. PubMed
19. Her Z, et al. 2014. EMBO Mol. Med. 7:24. PubMed
20. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
21. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations：
1. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
2. Amor C, et al. 2020. Nature. 583:127. PubMed
3. Martens CR, et al. 2022. PLoS Pathog. 18:e1010342. PubMed
4. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
5. Howard ZM, et al. 2022. JCI Insight. 7:. PubMed
6. Howard ZM, et al. 2021. Am J Pathol. 191:730. PubMed
7. Säwen P et al. 2018. eLife. 7 pii: e41258. PubMed
1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (FC)
2. Daley JM, et al. 2008. J. Leukocyte Biol. 83:1. (FC)
3. Dietlin TA, et al. 2007. J. Leukocyte Biol. 81:1205. (FC)
4. Daley J, et al. 2007. J. Leukocyte Biol. doi:10.1189. (Deplete) PubMed
5. Tadagavadi RK, et al. 2010. J. Immunol. 185:4904. PubMed
6. Sumagin R, et al. 2010. J. Immunol. 185:7057. PubMed
7. Guiducci C, et al. 2010. J. Exp Med. 207:2931. PubMed
8. Fujita M, et al. 2011. Cancer Res. 71:2664. PubMed
9. Van Leeuwen, et al. 2008. Arterioscler. Thromb. Vasc. Biol. 28:84. (IHC)
10. Kowanetz M, et al. 2010. P. Natl. Acad. Sci. USA 107:21248. [supplementary data] (IHC)
11. Esbona K, et al. 2016. Breast Cancer Res. 18:35. (IHC)
12. Wojtasiak M, et al. 2010. J. Gen. Virol. 91:2158. (FC, Deplete)
13. Jaeger BN, et al. 2012. J. Exp. Med. 209:565. (Deplete)
14. Wozniak KL, et al. 2012. BMC Immunol. 13:65 (FC, Deplete)
15. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
16. Ng LG, et al. 2011. J Invest. Dermatol. 131:2058. PubMed
17. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
18. McCartney-Francis, N, et al. 2014. J Leukoc. Biol. 96:917. PubMed
19. Her Z, et al. 2014. EMBO Mol. Med. 7:24. PubMed
20. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
21. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations：
1. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
2. Amor C, et al. 2020. Nature. 583:127. PubMed
3. Martens CR, et al. 2022. PLoS Pathog. 18:e1010342. PubMed
4. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
5. Howard ZM, et al. 2022. JCI Insight. 7:. PubMed
6. Howard ZM, et al. 2021. Am J Pathol. 191:730. PubMed
7. Säwen P et al. 2018. eLife. 7 pii: e41258. PubMed
文献支持
Fire™ 750 抗小鼠 Ly-6G 荧光标记APC 抗体
￥2300 - 5900
